Peter Marks (Greg Nash/Pool via AP Images)

FDA con­venes com­mit­tee of vac­cine ex­perts to con­sid­er a flu-like path for Omi­cron-spe­cif­ic boost­ers

Al­though the FDA signed off last week on a sec­ond Covid-19 boost­er shot for those who are over 50 years old, with­out first con­sult­ing its ad­vi­so­ry com­mit­tee of out­side vac­cine ex­perts, the agency is con­ven­ing the com­mit­tee on Wednes­day — as was planned pri­or to the sec­ond boost­er de­ci­sion — to dis­cuss next steps for an Omi­cron- or oth­er vari­ant-spe­cif­ic boost­er.

While the cur­rent­ly au­tho­rized and ap­proved Covid vac­cines (from Pfiz­er, Mod­er­na and J&J) are de­signed to elic­it a pro­tec­tive re­sponse to the virus that cir­cu­lat­ed ear­ly on in the pan­dem­ic, the ac­cu­mu­lat­ing da­ta sug­gest that the com­po­si­tion of vac­cines may need to be up­dat­ed, the FDA said ahead of to­mor­row’s meet­ing, “at some point to en­sure the high lev­el of ef­fi­ca­cy demon­strat­ed in the ear­ly vac­cine clin­i­cal tri­als.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.